Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer

Inclusion Criteria: * Histological or cytological confirmed pancreatic cancer. * Not eligible for curative resection. * No distant metastases present. * Previously untreated with chemotherapy and anti-cancer biologicals for current malignancy. * No other current malignant disease, except for basal cell carcinoma of the skin. * Measurable or evaluable disease as defined by RECIST 1.1 criteria. * Performance status 0-2 Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Scale. * Age ≥ 18 years. * Adequate haematological and biological functions: * Bone marrow function: 1. Neutrophils ≥ 1.5 x 109/L 2. Platelets ≥ 100 x 109/L 3. Hb ≥ 6 mmol/L * Hepatic function: 1. AST/ALT and alkaline phosphatase (ALP) ≤ 2.5 x institutional upper limit of normal (ULN) 2. Bilirubin ≤ 1.5 times institutional ULN * Renal function: eGFR \>50ml/min • Metabolic Function: 1. Magnesium ≥ lower limit of normal 2. Calcium ≥ lower limit of normal. * No imminent bowel obstruction. * No active bleeding. * No uncontrolled infection. * Patients with reproductive potential must use effective contraception. Female patients must have a negative pregnancy test. * Signed informed consent. Exclusion Criteria: * Participation in another therapeutic clinical study within 30 days of enrollment or during this clinical study. * No adequate radiation therapy possible: based on the opinion of the radiation oncologist when radiation therapy cannot be performed because radiation field is too large (PTV volume too large or OAR too high) * History of allergic reactions to gemcitabine or antibody treatment. * Presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled inter-current illness including ongoing or active infection, uncontrolled hypertension). * Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within 1 year before enrolment/randomization * History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan * Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance. * Pregnant or breastfeeding women. * Absence of adequate contraception for both male and female fertile patients for the duration of the study; and also for six months after last treatment. * Known positive status for HIV and/or hepatitis B or C. * Any reason why, in the investigator's opinion, the patient should not participate in the study. * Drug or alcohol abuse.